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Abstract
Objective: The aim was to study the thrombocytopenia in human immunodeficiency virus (HIV) infected children and its relation 
with WHO clinical and immunological HIV/AIDS staging. Study Design: Observational analytic cross-sectional study. Materials 
and Methods: 47 ambulatory and clinically stable HIV-infected children (confirmed by enzyme-linked immunosorbent assay for 
HIV-1 and HIV-2) aged 18 months-18 years attending the out-patient Department of anti-retroviral therapy center at tertiary care 
setting, were included in this study. Detailed history was taken, and thorough clinical examination was done in all cases. Blood sample 
for complete blood count and CD4 count was taken. Primary Outcome: Thrombocytopenia in HIV-infected children. Secondary 
Outcome: WHO clinical and immunological HIV/AIDS staging in HIV-infected children and its relation to thrombocytopenia. 
Results: Of 47 studied children, thrombocytopenia was found in 14 (29.78%) cases. Patients with thrombocytopenia were found in 
all stages of the disease; however, it was strongly associated with increasing immunological stages (correlation coefficient, r = 0.948). 
Conclusion: Thrombocytopenia commonly occurs in children with HIV and its occurrence increases with an increase in WHO clinical 
and immunological HIV/AIDS staging.
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Human immunodeficiency virus (HIV) infection is a worldwide problem but more so in developing countries. In India, the estimated number of children 
living with HIV increased from 1.42 lakhs in 2007 to 1.45 lakhs 
in 2011. Combination antiretroviral therapy access among 
children remains limited with only 15% of clinically eligible 
individuals received treatment in year 2006 [1]. Disorders of 
the hematopoietic system including anemia, leukopenia and/or 
thrombocytopenia are common throughout the course of HIV 
infection. Possible causes of cytopenias were inadequate 
production of the cells due to suppression of the bone marrow 
by the HIV infection through abnormal cytokine expression 
and alteration of the bone marrow microenvironment. The 
incidence and severity of cytopenia are generally correlated 
to the stage of the HIV infection [2]. Recent data suggest that 
impaired platelet production may be an important pathogenic 
mechanism responsible for the occurrence of thrombocytopenia 
in HIV-infected patients. The findings of megakaryocytic 
dysplasia in the bone marrow of thrombocytopenic patients 
together with evidence that HIV can infect megakaryocyte 
support this contention [3]. Thrombocytopenia may represent 
the first manifestation of HIV infection, and it may progress 
over time and lead to severe bleeding [4]. Therefore, we planned 
this study to observe the occurrence of thrombocytopenia in 
HIV-infected children and its relation with WHO clinical and 
immunological HIV/AIDS staging.
MATERIAL AND METHODS
47 ambulatory and clinically stable HIV-infected children 
(confirmed by enzyme-linked immunosorbent assay for HIV-1 
and HIV-2) aged 18 months-18 years attending the outpatient 
department of anti-retroviral therapy center at tertiary care 
setting, were included in the study. Written consent was taken 
from parents/guardian prior to investigation and for being 
part of the study. Parents and sibling’s HIV infection status 
were also enquired. Detailed history was taken, and complete 
physical examination of all the patients was done. Accordingly, 
patients were allocated in different stages of WHO clinical 
HIV/AIDS staging [5]. Absolute CD4 czount of each patient 
was done with Partec CyFlow® counter flow cytometer to 
assess the WHO immunological HIV/AIDS stage of the HIV-
infected child. Complete blood count was done on automated 
cell counter. Blood was collected in ethylenediamine tetraacetic 
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acid vial and mix for 5-10 min. Thrombocytopenia was defined 
as a reduction in platelet count to <150 × 109/L [6]. The platelet 
count was compared with pre-established mean values in 
children.
Sample Size
In our study, the primary outcome was thrombocytopenia 
in HIV-infected children. In previous studies, observed a 
prevalence of thrombocytopenia was 5-15% [7-12]. We have 
taken prevalence as a positive factor for sample size calculation, 
and the average prevalence of thrombocytopenia is 7.5%. 
Sample size calculation for qualitative data = 4.P.q/E2, where 
P is the positive factor (prevalence or incidence), which is taken 
7.5, q is 100−P = 100-7.5 = 92.5 and E is the allowable error, 
which vary from 10% to 20%, we kept it minimum as 10%. So, 
calculated sample size will be 28. Our sample size of 47 is more 
than the calculated sample size for valid and precise results.
Data Analysis
Data were analyzed using SPSS software (SPSS Inc., IBM, 
UK). To describe nominal data, simple percentages were 
used. Mean and standard deviations were used to describe 
normally distributed data from the subjects. The Spearman rank 
correlation test was used to determine the relationship between 
different continuous variables.
RESULTS
47 patients were enrolled in the study, out of which, 37 (78.7%) 
were male, and 10 (21.3%) were female with male to female 
ratio of 3.7:1. The mean age of patients was 6.64±3.59 years 
(range - 1.5-14 years). The most commonly involved age group 
was 1.5-5 years and almost half (46.81%) of the cases belong 
to this group. There was no case in the age group of 15-18 years 
(Table 1).
On clinical staging on the basis of WHO clinical staging 
criteria, 6 (12.76%) out of 47 cases were in Stage 1, 26 (55.31%) 
cases in Stage 2, 13 (27.66%) in Stage 3 and 2 (4.26%) cases 
were in Stage 4. On WHO immunological staging, 24 (51.06%) 
out of 47 cases were found in Stage 1, 9 (19.15%) cases 
each in Stage 2 and Stage 3 and 5 (10.63%) cases were in 
Stage 4. Thrombocytopenia was found in 14 (29.78%) cases. 
On studying its relation with WHO clinical stages, we find 
that thrombocytopenia had weak relation with increasing 
WHO clinical stages (correlation coefficient, r = 0.609). On 
the other hand, cases with thrombocytopenia were found in 
all the immunological stages of the disease and it was strongly 
associated with increasing immunological stages of the disease 
(correlation coefficient, r = 0.948) (Table 2).
DISCUSSION
Thrombocytopenia is a common hematologic finding in patients 
infected with the HIV. Multiple mechanisms may contribute to 
the development of thrombocytopenia as immune-mediated 
platelet destruction, enhanced platelet splenic sequestration, 
and impaired platelet production.
In our study, 14 (29.78%) patients had thrombocytopenia 
while Suarez et al. [13] noted thrombocytopenia in 27% 
cases and Silva et al. [14] in 25% cases. Many authors have 
reported lower prevalence of thrombocytopenia (5-15%) in 
HIV seropositive patients [7-12]. We noted high prevalence of 
thrombocytopenia in our study when compared to other studies 
of western countries. This may be due to the better immune 
status of children in western countries when compared to 
children in Indian scenario.
The highest incidence of thrombocytopenia (100%) 
was seen in WHO clinical Stage 4. Mir et al. [15] reported 
thrombocytopenia in 61% cases in the advanced stage. The 
progression of thrombocytopenia was more strongly associated 
(correlation coefficient, r = 0.948) with immunological 
advancement of the disease as compared to clinical progression 
of the disease (correlation coefficient, r = 0.609). In the 
present study, with decreasing CD4 counts, prevalence of 
thrombocytopenia was increasing. It means the prevalence 
of thrombocytopenia was proportionally high among patients 
who had low CD4 lymphocyte count and vice-versa. Similar 
findings have been reported by Wondimeneh et al. [16].
Table 1: Distribution of cases by age and sex
Age group Male (%) Female (%) Total (%)
1.5-5 year 18 (38.30) 4 (8.51) 22 (46.81)
5-10 year 13 (27.66) 4 (8.51) 17 (36.17)
10-15 year 6 (12.77) 2 (4.25) 8 (17.02)
Total 37 (78.73) 10 (21.27) 47 (100)
Table 2: Distribution of cases with thrombocytopenia in relation to WHO clinical staging and immunological staging
WHO clinical 
stages
Thrombocytopenia 
n (%)
WHO immunological 
stages
Thrombocytopenia 
n (%)
Stage 1 (n=6) 2 (33.33) Stage 1 (n=24) 6 (25.0)
Stage 2 (n=26) 7 (26.92) Stage 2 (n=9) 3 (33.33)
Stage 3 (n=13) 3 (23.07) Stage 3 (n=9) 3 (33.33)
Stage 4 (n=2) 2 (100) Stage 4 (n=5) 2 (40.0)
Total (n=47) 14 (29.79) Total (n=47) 14 (29.79)
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CONCLUSION
This study has provided additional information with regard to 
the occurrence of thrombocytopenia in HIV-infected children. 
As CD4 counts of HIV patients decreasing, they have more 
likely to have thrombocytopenia. Therefore, early diagnosis 
and treatment of thrombocytopenia is necessary to prevent the 
bleeding problems associated with the thrombocytopenia in 
HIV-infected children.
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